Linagliptin also increased renal SDF-1 expression and plasma SDF-1 levels in rats with obesity-related nephropathy, with concomitant reductions in renal DPP-4 activity, damage to the glomerular filtration barrier, and proteinuria [69]. This evidence concerns the gene CXCL12 and kidney disorder.